in vitro and in vivo activity of solithromycin (CEM-101) against plasmodium species

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 703-707

  Wittlin, Sergio ^a,b   Ekland, Eric ^c   Craft, J Carl ^d   Lotharius, Julie ^e   Bathurst, Ian ^e   Fidock, David A ^c   Fernandes, Prabhavathi ^d  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Department of Medicine   (United States)

^d Cempra Pharmaceuticals   (United States)

^e Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; AZITHROMYCIN; CHLOROQUINE; CLINDAMYCIN; PYRIMETHAMINE; QUININE; SOLITHROMYCIN; SULFADOXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; APICOPLAST; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; DRUG POTENCY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARASITE CLEARANCE; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASTID GENOME; PRIORITY JOURNAL; RIBOSOME; RODENT MALARIA; SINGLE DRUG DOSE;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; HUMANS; MACROLIDES; MALARIA; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; TRIAZOLES;

EID: 84856075532     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05039-11     Document Type: Article

References (34)

1. Bertrand D, Bertrand S, Neveu E, Fernandes P. 2010. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54: 5399-5402.
2. Charman SA, et al. 2011. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. U. S. A. 108:4400-4405.
3. Dahl EL, Rosenthal PJ. 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51:3485-3490. (Pubitemid 47519333)
4. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718. (Pubitemid 10082023)
5. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
6. Dubois J, Fernandes P. 2010. CEM-101, a novel ketolide; in vitro activity against resistant strains of Streptococcus pneumoniae and Haemophilus influenzae, abstr p-904. Abstr. 20th Eur. Congr. Clin. Microb. Infect. Dis.
7. Dubois J, Fernandes P. 2009. In vitro activity of CEM-101 against resistant strains of Staphylococcus aureus, abstr F1-2037. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7:864-874.
9. Ekland EH, Fidock DA. 2007. Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol. 10:363-370. (Pubitemid 47404958)
10. Ekland EH, Schneider J, Fidock DA. 2011. Identifying apicoplasttargeting antimalarials using high-throughput compatible approaches. FASEB J. 25:3583-3593.
11. Farrell DJ, et al. 2010. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int. J. Antimicrob. Agents 35:537-543.
12. Franke-Fayard B, et al. 2004. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 137:23-33. (Pubitemid 38987939)
13. Huber W, et al. 1993. Sensitivity of Plasmodium falciparum field-isolates from Tanzania to chloroquine, mefloquine and pyrimethamine during in vitro cultivation. Acta Trop. 52:313-316. (Pubitemid 23043721)
14. Kalanon M, McFadden GI. 2010. Malaria, Plasmodium falciparum and its apicoplast. Biochem. Soc. Trans. 38:775-782.
15. Lell B, Kremsner PG. 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. 46:2315-2320. (Pubitemid 34793429)
16. Lemaire S, Van Bambeke F, Tulkens PM. 2009. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob. Agents Chemother. 53:3734-3743.
17. Llano-Sotelo B, et al. 2010. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob. Agents Chemother. 54:4961-4970.
18. Matile H, Pink JRL. 1990. Plasmodium falciparum malaria parasite cultures and their use in immunology, p. 221-234. In B. Pernis (ed.), Immunological methods, vol. 4. Academia Press, San Diego, CA.
19. McGhee P, et al. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238.
20. Noedl H, et al. 2006. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin. Infect. Dis. 43:1264-1271. (Pubitemid 44706451)
21. Noedl H, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
22. Noedl H. 2009. ABC-antibiotics-based combinations for the treatment of severe malaria? Trends Parasitol. 25:540-544.
23. Noedl H, Socheat D, Satimai W. 2009. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361:540-541.
24. O'Brien C, Henrich PP, Passi N, Fidock DA. 2011. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24:570-577.
25. Pereira DP, Degenhardt T, Fernandes P. 2010. Comparison of CEM-101 metabolism in mice, rats, monkeys and humans, abstr A-687. Abstr 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Peters W. 1987. Chemotherapy and drug resistance in malaria, 2nd ed. Academic Press, London, United Kingdom.
27. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M. 2011. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int. J. Antimicrob. Agents 37:39-45.
28. Ridley RG, et al. 1997. Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Antimicrob. Agents Chemother. 41:677-686. (Pubitemid 27098424)
29. Scott JA, et al. 2011. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 378:1316-1323.
30. Sidhu AB, et al. 2007. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282:2494-2504. (Pubitemid 47076745)
31. Still JG, et al. 2011. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob. Agents Chemother. 55:1997-2003.
32. White NJ. 1999. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41:301-308.
33. Yeh E, Derisi JL. 2011. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 9:e1001138.
34. Yeo AE, Rieckmann KH. 1995. Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int. J. Parasitol. 25:531-532.